Results 51 to 60 of about 4,811,177 (246)

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance

International Journal of Molecular Sciences, 2020
Among classical BCR-ABL-negative myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) is the most aggressive subtype from a clinical standpoint, posing a great challenge to clinicians. Whilst the biological consequences of the three MPN driver
E. Rumi, C. Trotti, D. Vanni, I. Casetti, D. Pietra, Emanuela Sant'Antonio   +5 more
semanticscholar   +1 more source

Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis

European Journal of Haematology, 2020
COVID‐19 carries a high risk of severe disease course, particularly in patients with comorbidities. Therapy of severe COVID‐19 infection has relied on supportive intensive care measures. More specific approaches including drugs that limit the detrimental
S. Koschmieder, E. Jost, C. Cornelissen, Tobias Müller, M. Schulze-Hagen, J. Bickenbach, G. Marx, M. Kleines, N. Marx, T. Brümmendorf, M. Dreher   +10 more
semanticscholar   +1 more source

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Leukemia, 2018
International collaborations over the years have produced a series of prognostic models for primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced international prognostic scoring systems for transplant-age patients (MIPSS70 and ...
A. Tefferi, P. Guglielmelli, M. Nicolosi, F. Mannelli, M. Mudireddy, N. Bartalucci, C. Finke, T. Lasho, C. Hanson, R. Ketterling, K. Begna, N. Gangat, A. Pardanani, A. Vannucchi   +13 more
semanticscholar   +1 more source

Targeted sequencing of candidate gene regions for myelofibrosis in dogs

Journal of Veterinary Internal Medicine, 2022
Background Myelofibrosis often lacks an identifiable cause in dogs. In humans, most primary myelofibrosis cases develop secondary to driver mutations in JAK2, CALR, or MPL.
Amelia G. Campbell, Davis M. Seelig, Joan D. Beckman, Katie M. Minor, Daniel A. Heinrich, Steven G. Friedenberg, Jaime F. Modiano, Eva Furrow   +7 more
doaj   +1 more source

Primary autoimmune myelofibrosis: A case report in a child

eJHaem, 2020
Autoimmune myelofibrosis (AIMF) is an uncommon cause of myelofibrosis associated with favorable outcome. Primary AIMF, AIMF without a known systemic autoimmune disorder, has been described in adults, but never in children. Here, we present, for the first
Zufit Hexner‐Erlichman, Joanne Yacobovich, Philippe Trougouboff, Moran Avraham‐Kelbert, Harel Eitam, Ronen Spiegel, Shay Yeganeh, Carina Levin   +7 more
doaj   +1 more source

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

Haematologica, 2011
Risk stratification in primary myelofibrosis is currently based on two international prognostic scoring systems, neither of which takes into consideration red blood cell transfusion-dependency.
Chiara Elena, Francesco Passamonti, Elisa Rumi, Luca Malcovati, Luca Arcaini, Emanuela Boveri, Michele Merli, Daniela Pietra, Cristiana Pascutto, Mario Lazzarino   +9 more
doaj   +1 more source

ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS

Acta Biomedica Scientifica, 2017
Ph-negative myeloproliferative neoplasm are the group of hematologic disorders which includes primary myelofibrosis, polycythemia vera, essential trombocytemia and several rare diseases.
A. N. Alekseeva, O. E. Ochirova, L. B. Sodnomova, E. B. Zhalsanova   +3 more
doaj   +1 more source

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Blood, 2019
Anemia of lower-risk myelodysplastic syndromes (MDSs) and primary myelofibrosis (PMF) generally becomes resistant to available treatments, leading to red blood cell (RBC) transfusions, iron overload, shortened survival, and poor quality of life.
P. Fenaux, J. Kiladjian, U. Platzbecker
semanticscholar   +1 more source

Transforming growth factor β‐mediated micromechanics modulates disease progression in primary myelofibrosis

Journal of Cellular and Molecular Medicine, 2020
Primary myelofibrosis (PMF) is a Ph‐negative myeloproliferative neoplasm (MPN), characterized by advanced bone marrow fibrosis and extramedullary haematopoiesis.
Patric Teodorescu, Sergiu Pasca, A. Jurj, Grigore-Aristide Gafencu, J. Jóelsson, S. Selicean, C. Moldovan, R. Munteanu, Anca Onaciu, A. Țigu, Mihail Buse, Alina-Andreea Zimta, R. Știufiuc, B. Petrushev, Minodora Desmirean, D. Dima, C. Vlad, J. Bergthórsson, C. Berce, S. Ciurea, G. Ghiaur, C. Tomuleasa   +21 more
semanticscholar   +1 more source

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase

Haematologica, 2014
Myelofibrosis is a myeloproliferative neoplasm that occurs de novo (primary myelofibrosis) or results from the progression of polycythemia vera or essential thrombocytemia (hereafter designated as secondary myelofibrosis or post-polycythemia vera ...
Mandy Brecqueville, Jérôme Rey, Raynier Devillier, Arnaud Guille, Rémi Gillet, José Adélaide, Véronique Gelsi-Boyer, Christine Arnoulet, Max Chaffanet, Marie-Joelle Mozziconacci, Norbert Vey, Daniel Birnbaum, Anne Murati   +12 more
doaj   +1 more source